We are live on ! Find out more
GTHX

G1 Therapeutics, Inc. Common Stock
GTHX

Delisted

GTHX was delisted on the 17th of September, 2024.

Back to rankings

72 hedge funds and large institutions have $15.8M invested in G1 Therapeutics, Inc. Common Stock in 2023 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 23 increasing their positions, 21 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

613% more call options, than puts

Call options by funds: $585K | Put options by funds: $82K

10% more repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 21

10% less funds holding

Funds holding: 80 → 72 (-8)

35% less first-time investments, than exits

New positions opened: 11 | Existing positions closed: 17

59% less capital invested

Capital invested by funds: $38.6M → $15.8M (-$22.8M)

Holders
72
Holders Change
-8
Holders Change %
-10%
% of All Funds
1.14%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
11
Increased
23
Reduced
21
Closed
17
Calls
$585K
Puts
$82K
Net Calls
+$503K
Net Calls Change
-$279K

Top Buyers

Rank Fund Capital Flow
1
Marshall Wace
Marshall Wace
United Kingdom
+$892K
2
Millennium Management
Millennium Management
New York
+$853K
3
XT
XTX Topco
Cayman Islands
+$361K
4
Two Sigma Advisers
Two Sigma Advisers
New York
+$259K
5
RJA
Raymond James & Associates
Florida
+$259K

Top Sellers

Rank Fund Capital Flow
1
Fisher Asset Management
Fisher Asset Management
Washington
-$6.33M
2
JP Morgan Chase
JP Morgan Chase
New York
-$4.08M
3
GCP
GSA Capital Partners
United Kingdom
-$477K
4
Charles Schwab
Charles Schwab
California
-$422K
5
WP
Woodline Partners
California
-$375K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$2.81M – – –
BlackRock
2
BlackRock
New York
$1.61M -$126K -65,338 -6%
Millennium Management
3
Millennium Management
New York
$1.51M +$853K +440,930 +73%
RJA
4
Raymond James & Associates
Florida
$1.33M +$259K +133,662 +17%
Jacobs Levy Equity Management
5
Jacobs Levy Equity Management
New Jersey
$825K +$156K +80,480 +16%
Marshall Wace
6
Marshall Wace
United Kingdom
$744K +$892K +461,128 +829%
D.E. Shaw & Co
7
D.E. Shaw & Co
New York
$727K -$216K -111,421 -18%
Renaissance Technologies
8
Renaissance Technologies
New York
$683K -$189K -97,711 -17%
Geode Capital Management
9
Geode Capital Management
Massachusetts
$635K +$17.4K +8,981 +2%
XT
10
XTX Topco
Cayman Islands
$427K +$361K +186,753 +170%
Bank of America
11
Bank of America
North Carolina
$415K -$62.1K -32,081 -10%
NIM
12
Needham Investment Management
New York
$337K – – –
Two Sigma Advisers
13
Two Sigma Advisers
New York
$313K +$259K +134,000 +161%
Connor, Clark & Lunn Investment Management (CC&L)
14
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$294K +$160K +82,879 +68%
LFAS
15
Level Four Advisory Services
Texas
$264K +$185K +95,500 +109%
State Street
16
State Street
Massachusetts
$232K – – –
DA
17
Denali Advisors
California
$214K +$158K +81,700 +122%
Citadel Advisors
18
Citadel Advisors
Florida
$203K -$2.11K -1,090 -0.8%
BCM
19
Bridgeway Capital Management
Texas
$202K +$48.4K +25,000 +22%
Acadian Asset Management
20
Acadian Asset Management
Massachusetts
$189K +$255K +131,585 New
BC
21
Birchview Capital
Vermont
$173K +$155K +80,000 +200%
Northern Trust
22
Northern Trust
Illinois
$143K -$714 -369 -0.4%
Two Sigma Investments
23
Two Sigma Investments
New York
$130K +$175K +90,400 New
FSA
24
Franklin Street Advisors
North Carolina
$120K +$94.8K +49,000 +142%
Dimensional Fund Advisors
25
Dimensional Fund Advisors
Texas
$107K -$17.1K -8,843 -11%
1
2 3 4

GTHX Hedge Fund Activity: Q3 2023 in Review

72 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in G1 Therapeutics, Inc. Common Stock (GTHX) for Q3 2023, worth a combined $15.8M — down 59% from $38.6M a quarter earlier.

Sellers outnumbered buyers: 17 funds closed out of GTHX and 11 opened new positions — a net loss of 6 holders — while 21 trimmed existing stakes and 23 added.

The largest buyer was Marshall Wace, adding an estimated $892K. The largest seller was Fisher Asset Management, exiting entirely with an estimated $6.33M sold.

  • 72 institutional investors held G1 Therapeutics, Inc. Common Stock (GTHX) as of Q3 2023, down from 80 in Q2 2023.
  • Funds reported $15.8M of G1 Therapeutics, Inc. Common Stock stock for Q3 2023, down 59% quarter-over-quarter.
  • 11 funds opened new G1 Therapeutics, Inc. Common Stock positions in Q3 2023 and 17 closed out, a net change of -6 holders.
  • The largest G1 Therapeutics, Inc. Common Stock buyer in Q3 2023 was Marshall Wace, an estimated $892K added.
  • The largest G1 Therapeutics, Inc. Common Stock seller in Q3 2023 was Fisher Asset Management, an estimated $6.33M sold.

Based on aggregated 13F filings for Q3 2023.